Tetragon Partners GP Ltd
Tetragon Partners GP Ltd reported 32 US-listed holdings worth $614.3 million in its 13F for the quarter ended 30 June 2026, filed 13 August 2026. Its largest: UiPath, Inc. (54.8%), Kolibri Global Energy Inc. (5.5%) and Autolus Therapeutics PLC (2.5%). Against the quarter before, it opened 5 positions, added to 15, trimmed 5 and sold out of 7.
Filed before as TFG Asset Management GP Ltd.
The 14 largest of its 32 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned +14.8% over the 7 quarters to 30 June 2026, against +30.2% for the S&P 500.
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 5
- Alkami Technology Inc. ALKT$10.9 million
- Celcuity Inc. CELC$6.7 million
- Cue Biopharma Inc. Com CUE$3.0 million
- Aclaris Therapeutics Inc. ACRS$2.1 million
- Monte Rosa Therapeutics Inc. GLUE$1.4 million
Added to 15
- UiPath, Inc. PATH+5.7 million shares · +23%
- Relay Therapeutics Inc. RLAY+388,768 shares · +214%
- Ionis Pharmaceuticals Inc. IONS+55,409 shares · +133%
- Definium Therapeutics Inc. DFTX+86,996 shares · +43%
- MBX Biosciences Inc. MBX+58,063 shares · +40%
- Harmony Biosciences Holdings, Inc. HRMY+81,696 shares · +68%
- Pharvaris N V PHVS+74,016 shares · +33%
- Dyne Therapeutics Inc. DYN+98,525 shares · +38%
and 7 more in the table below
Trimmed 5
- Warner Bros Discovery Inc. WBD-673,725 shares · -73%
- Nektar Therapeutics NKTR-16,041 shares · -16%
- Celldex Therapeutics Inc. CLDX-21,875 shares · -7%
- Amylyx Pharmaceuticals Inc. AMLX-19,951 shares · -6%
- Annexon Inc. ANNX-50,000 shares · -4%
Sold out of 7
- Praxis Precision Medicines I PRAX$5.1 million last quarter
- Soleno Therapeutics Inc. SLNO$3.4 million last quarter
- Axsome Therapeutics Inc. AXSM$3.4 million last quarter
- Maplight Therapeutics Inc. MPLT$2.3 million last quarter
- Aardvark Therapeutics Inc. AARD$1.2 million last quarter
- Ultragenyx Pharmaceutical in RARE$826,959 last quarter
- Karyopharm Therapeutics Inc. KPTI$295,121 last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| UiPath, Inc. PATH | 30.9M | $336.4 million | 54.76% | +5.7M |
| Kolibri Global Energy Inc. KGEI | 6.8M | $33.8 million | 5.51% | no change |
| Autolus Therapeutics PLC AUTL | 9.5M | $15.2 million | 2.47% | no change |
| Lyft, Inc. LYFT | 1.0M | $14.6 million | 2.38% | no change |
| Definium Therapeutics Inc. DFTX | 287.0K | $13.5 million | 2.20% | +87.0K |
| Workiva Inc. WK | 250.0K | $12.1 million | 1.97% | no change |
| Sprinklr, Inc. CXM | 2.2M | $11.4 million | 1.85% | no change |
| MBX Biosciences Inc. MBX | 203.5K | $11.2 million | 1.83% | +58.1K |
| Alkami Technology Inc. ALKT | 600.3K | $10.9 million | 1.77% | new |
| Celldex Therapeutics Inc. CLDX | 290.4K | $10.8 million | 1.76% | -21.9K |
| Relay Therapeutics Inc. RLAY | 570.3K | $10.7 million | 1.74% | +388.8K |
| Arrowhead Pharmaceuticals, Inc. ARWR | 130.5K | $10.6 million | 1.73% | +3.3K |
| Pharvaris N V PHVS | 295.6K | $10.2 million | 1.66% | +74.0K |
| Alkermes plc. ALKS | 190.0K | $10.0 million | 1.62% | +30.2K |
| Immunovant Inc. IMVT | 255.9K | $9.9 million | 1.61% | +37.4K |
| Silence Therapeutics PLC SLN | 764.3K | $8.4 million | 1.37% | +134.1K |
| Dyne Therapeutics Inc. DYN | 356.7K | $7.9 million | 1.29% | +98.5K |
| Ionis Pharmaceuticals Inc. IONS | 97.2K | $7.7 million | 1.25% | +55.4K |
| Agios Pharmaceuticals Inc. AGIO | 205.6K | $7.6 million | 1.24% | +40.7K |
| Harmony Biosciences Holdings, Inc. HRMY | 201.0K | $7.3 million | 1.19% | +81.7K |
| Krystal Biotech, Inc. KRYS | 19.7K | $7.3 million | 1.19% | no change |
| Annexon Inc. ANNX | 1.2M | $7.1 million | 1.15% | -50.0K |
| Celcuity Inc. CELC | 64.1K | $6.7 million | 1.09% | new |
| Warner Bros Discovery Inc. WBD | 250.0K | $6.7 million | 1.08% | -673.7K |
| Nektar Therapeutics NKTR | 87.0K | $6.1 million | 0.99% | -16.0K |
| Amylyx Pharmaceuticals Inc. AMLX | 297.9K | $5.4 million | 0.87% | -20.0K |
| Acadia Pharmaceuticals Inc. ACAD | 167.9K | $4.2 million | 0.69% | +23.3K |
| Cue Biopharma Inc. Com CUE | 93.8K | $3.0 million | 0.48% | new |
| Snowflake Inc. SNOW | 10.0K | $2.5 million | 0.41% | no change |
| Aclaris Therapeutics Inc. ACRS | 400.0K | $2.1 million | 0.34% | new |
| Tectonic Therapeutic Inc. TECX | 46.5K | $1.6 million | 0.26% | +8.9K |
| Monte Rosa Therapeutics Inc. GLUE | 56.1K | $1.4 million | 0.22% | new |
Read more
Change is shares against its 13F for the quarter before; the 7 it sold out of are in the box above.Options it reported
| Company | Option | Shares under the options | Value of those shares |
|---|---|---|---|
| Axsome Therapeutics Inc. AXSM | Calls | 35.0K | $8.6 million |
| Ultragenyx Pharmaceutical in RARE | Calls | 100.0K | $3.3 million |
| Silence Therapeutics PLC SLN | Calls | 300.0K | $3.3 million |
| Karyopharm Therapeutics Inc. KPTI | Calls | 250.3K | $2.4 million |
| Agios Pharmaceuticals Inc. AGIO | Calls | 50.0K | $1.9 million |
| Tenax Therapeutics Inc. TENX | Calls | 75.1K | $1.1 million |
| Amylyx Pharmaceuticals Inc. AMLX | Calls | 8.5K | $152,660 |
7 option lines. A 13F lists calls and puts by the shares they cover and what those shares were worth at the quarter's end, not what the options cost; they are not counted in the holdings above.